ACADIA Pharmaceuticals Inc. — Biomedical Watch V2

Traitements5programmes

Essais3liés

Publications3liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
ACP-103The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis. The secondary objectives are to determine whether ACP-103 will ameliorate psychosis in patients with Parkinson's disease and whether ACP-103 is safe in Parkinson's disease patients taking multiple anti-parkinsonian medications.	Parkinson	Phase 2	À vérifier	United States	À vérifier
ACP-204This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.	Alzheimer	Phase 2/3	À vérifier	United States, Brazil, Bulgaria, Chile, Czechia, France, Italy, Mexico, …	À vérifier
ACP-103The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis. The secondary objectives are to determine whether ACP-103 will ameliorate psychosis in patients with Parkinson's disease and whether ACP-103 is safe in Parkinson's disease patients taking multiple anti-parkinsonian medications.	Parkinson	Phase 2	À vérifier	United States	À vérifier
ACP-204This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.	Alzheimer	Phase 3	À vérifier	United States, Brazil, Bulgaria, Chile, Czechia, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan	À vérifier
ACP-204This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.	Alzheimer	Phase 2/3	À vérifier	United States, Brazil, Bulgaria, Chile, Czechia, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan	À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
ACP-204	Alzheimer	Phase 2/3	NCT06159673	ACP-204 in Adults With Alzheimer's Disease Psychosis	RECRUITING
ACP-204	Alzheimer	Phase 3	NCT06194799	ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study	ENROLLING_BY_INVITATION
ACP-103	Parkinson	Phase 2	NCT00087542	Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug	COMPLETED

Publications

3

Molécule	Indication / population	Titre	Journal	Date
ACP-103		Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations.	European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
ACP-103		The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia.	Biomolecules
ACP-103		Unlocking the potential of lumateperone and novel anti-psychotics for schizophrenia.	BioImpacts : BI